Cisa Research

Cisa Group strives every day to make infection control safer and more efficient.
Cisa Research is the beating heart of our corporate innovation. It is our hub for research and development. This is where special and customized projects for the sterilization process are created and evolve. This is where we implement cutting-edge technical solutions for thermal disinfection and decontamination and for processes destined to become tomorrow’s benchmarks in the healthcare, pharmaceutical and laboratory industries and in research labs.

The DNA of innovation

Technological innovation is a process that affects every single component of Cisa Group’s technologies for the sterilization process.
Autoclaves, washer-disinfectors and all products are constantly subjected to studies and tests that improve their planning, design and concept.
The will to innovate embraces the ethical principles in which the company recognises itself. Cisa Group is aware that its work impacts the lives of others every day, and takes into account the interests of its customers, the safety of their operators, the health of patients and sustainable development.

The Cisa Research team

The approach is based on resourcefulness and a proactive attitude, on the skills and knowledge of its employees and on the diversity of their contribution.

Cisa Research has a heterogeneous team that deals with electrical, civil and biomedical engineering, and collaborates with market-leading partners and highly specialised expert professionals, institutions, universities and research centres in the healthcare industry and in the world of life science.

In this space dedicated to optimizing the sterilization process, the Cisa Group of the future is growing. Here we already meet today the needs of tomorrow’s infection control. We care about Life.

40+

TECHNICIANS

30+

ENGINEERS

8%

INVESTMENT INDEX IN R&D

5

Prizes awarded in the last few years

12

PATENTS

Own Software

systems compliant with the requirements of the TRANSITION TO INDUSTRY 4.0

European Call

for proposals and development programs for its innovative approach to systems and processes.

Africa Health

finalist
for new
Aquazero

2016

Region of Tuscany call

proposal with the (?.?.?.?.?.?.?. ??????? ????????? ??????? ??? ????????????? ????? ?? ? ???? ???????? )

2017

Region of Tuscany
Innovation Award

the (?.?.?.?.?.?.?.)
project

2019

Artes call for proposal III
with the I-CSSD project

second
place

2020

C.A.P.S.U.L.A.
Call for proposal

R&D project, in partnership, in the healthcare/biomedical sector, aimed at developing new solutions for automation and robotization in the disinfection and sterilisation of surgical instruments with an integrated approach to the Industry 4.0 philosophy.

Project implementation period: 2017-2020
Total project budget: € 3,017,155.48
Cisa Production S.r.l. budget: € 1,086,839.60
Financial support received by Cisa Production S.r.l.: €. 326,051.88

DOWNLOAD →

C.A.P.S.U.L.A: the CSSD concept of the future

The C.A.P.S.U.L.A. (Central Automated Process for Sterilization Units in a Lean Activity) project implements an innovative transport system, fully automatic and robotised, for surgical instruments and medical devices.

The prototype is based on the logistical handling of a container active in the washing and sterilization process (the capsule – advanced capsule), which itself becomes the chamber of the CSSD.

By means of AIV (Automated Intelligent Vehicle) connections and handling systems, and with the aid of anthropomorphic robots, the C.A.P.S.U.L.A. containers go through the classic reprocessing procedure in a single environment.

This difference is significant compared to a traditional CSSD, which is usually divided into 3 areas (dirty area, clean area, sterile area): the sterilization capsule occupies a totally different space.

The C.A.P.S.U.L.A. project totally redesigns the CSSD: spaces and processes change, a new, safer, more standardised operating experience is offered.

For more information, contact Cisa Group’s Research team.

AIOT per dispositivi medici

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed venenatis enim pretium mauris sodales hendrerit non sed magna. Morbi cursus diam eget mattis semper. Mauris fringilla orci quis nunc congue, quis molestie mauris lacinia. Nunc vitae dignissim dolor.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Autoapprendimento proattivo dei macchinari nelle procedure e nei processi in sanità

Automazione per applicazioni sanitarIe

Gemello Digitale in ospedale

CSSD e integrazione in sala operatoria

Medical Waste Treating 4.0

R&D project aimed at the creation of an innovative automated system for the treatment and ennobling of medical waste in an End-of-Waste perspective.

Project implementation period: 2020-2022
Total project budget: € 2,898,129.18
Cisa Production S.r.l. budget: € 1,151,079.60

Financial support received by Cisa Production S.r.l.: €. 287,769.90

DOWNLOAD →

Waste treatment 4.0.
The end-of-waste solution for infectious medical waste

One of the highest costs for hospitals from a financial and environmental point of view is determined by the treatment process of medical waste.
In Italy, the numbers are high: we are talking about an average annual production of almost 150,000 tonnes, which has practically doubled since the Covid-19 pandemic. The management and disposal of this enormous quantity of medical waste therefore becomes a complex, hazardous and also expensive procedure. It involves locating large storage areas and organising numerous transports to treatment facilities. This has an impact on costs and on the environment.

Cisa’s Waste technology solutions already address these issues, and the Waste treatment 4.0 project looks beyond by taking into account some current trends:

recent regulations on medical waste have provided the opportunity for a smart management by making it subject to the legal regime of municipal waste if properly treated and sterilised on-site

the sterilisation of hazardous medical waste must be as widespread as possible and preferably carried out on-site

the medical waste treatment processes of the future in a circular economy aim at the production of new high-value products through differentiation and ennobling of medical waste.

Cisa Group’s Medical WasteTreating 4.0 (MWT4.0) project goes beyond the conversion of medical waste into a less hazardous class and the use of sterilization as a treatment method for infectious risk, and represents the next radical revolution in management processes. Medical WasteTreating 4.0 is an integrated medical waste treatment and ennobling in an end-of-waste perspective, consistent with the principles of Industry 4.0 applied to the healthcare and life science industry.

The foundations have been identified in the convergence of technological developments in three areas of industrial interest: advanced materials, advanced automation and ICT.

The target is the identification of ways leading to the loss of waste status and the transformation into new valuable raw materials..

MWT4.0 consists of integrated prototypes that create a smart factory system which affects the entire life cycle of medical waste: from waste production in clinics, operating blocks, wards, to its collection and sorting, until it ceases to be waste and becomes new raw material or secondary solid fuel. For more information, contact Cisa Group’s Research team.

3D printing and Cisa Group: a new perspective applied to the sterilisation process industry

After tests with its first 3D printer and the study of biodegradable and eco-friendly materials, Cisa Group went from making prototypes to producing small finished parts for use within its sterilization technologies.

The company then decided to implement the use of a professional printer and high-quality filaments.

“We conducted studies and research. We distinguished materials by selecting those with the best technical, mechanical, chemical and thermal features” says Gabriele Lucchesi, Technical Mechanical Department, Cisa Group.
“This allows us to produce fully customisable parts in a short time. Components can have new layouts that are unthinkable with conventional production methods. All this allows us to improve performance by continuously optimising our technologies for the healthcare industry and our solutions for life science”, concludes Gabriele.
Cisa Group invests heavily in research and development, and Cisa Research keeps a watchful eye on the future of infection control. Innovation and material development also allow us to look to the future by identifying new elements that can bring significant benefits and advantages in sterilization process applications.

find out more

for further information

Cisa Research

The DNA of innovation

The Cisa Research team

40+

30+

8%

5

12

Own Software